News & Updates

Treatment with tenofovir alafenamide (TAF) for pregnant women with active chronic hepatitis B (CHB) infection, when administered throughout or initiated early in pregnancy, is effective and safe in both mothers and infants, according to a study.

Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.